ZICOM GROUP LIMITED — Capital/Financing Update 2017

Feb 20, 2017

ABN 62 009 816 871 Zicom Group Limited

==> picture [64 x 16] intentionally omitted <==

==> picture [64 x 16] intentionally omitted <==

==> picture [64 x 16] intentionally omitted <==

38 Goodman Place, Murarrie, Queensland 4172 • Tel: (07) 3908 6088 • Fax: (07) 3390 6898

21 February 2017

Market Announcement Office Australian Securities Exchange Level 6, 20 Bridge Street SYDNEY NSW 2000

Dear Sirs,

Investment in Disruptive Glaucoma Therapy Device

We are pleased to announce that the Group’s wholly owned subsidiary, Zicom MedTacc Pte Ltd (“MedTacc), an appointed Medtech Accelerator, will invest USD$1.01m in a growth phase medical technology start-up, Belkin Laser Ltd (“Belkin”) based in Israel. The Group is open to follow-up investments in the future.

Belkin Laser Ltd is a medical device company founded by accomplished world renowned ophthalmologist, Emeritus Professor Michael Belkin of Tel-Aviv University who is the director of the Ophthalmic Technologies Laboratory at the University’s Eye Research Institute, located at the Sheba Medical Center, Israel. Belkin Laser is developing a laser treatment for glaucoma that can be performed in one second. This technology is aimed at revolutionizing access to glaucoma care by becoming the first-line choice for glaucoma therapy for every patient and making glaucoma laser treatment more accessible through general ophthalmologists. Glaucoma is the second leading cause of blindness in the world according to the World Health Organisation.

The aim is to leverage on our Group’s presence and network in the Asia Pacific region to carry out clinical trials and secure regulatory approval, so as to complement the efforts of Belkin Laser, Israel, which focuses on Europe and USA and make this technology available to the masses in Asia and globally.

Belkin Laser is one of the winners for the EU Horizon 2020 grant for its invention. The grant amounts to Euros 2.5m and is non-dilutive.

This investment has been fully funded from internal resources without external borrowings. It is part of the Group’s strategy of expansion into new innovations and technologies with focus on medical technologies for the medium to long term.

The Board does not expect the investment to have any immediate impact on the Group’s earnings in the short term.

Yours faithfully Zicom Group Limited

==> picture [36 x 50] intentionally omitted <==

-------------------------------G L Sim Chairman

1